← Back to Search

Monoclonal Antibodies

Tiragolumab for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

This trial is testing a new immunotherapy drug to see if it's safe and works well against certain blood cancers.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma
  • B-Cell Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With Adverse Events
Secondary outcome measures
ORR for R/R NHL
Objective Response Rate (ORR) for R/R MM
Percentage of Participants With ADAs to Atezolizumab
+3 more

Trial Design

5Treatment groups
Experimental Treatment
Group I: Arm E: Tiragolumab + Atezolizumab + Daratumumab R/R MMExperimental Treatment3 Interventions
Participants with R/R MM will receive 600 mg tiragolumab Q3W + atezolizumab by IV infusion Q3W + daratumumab by SC injection.
Group II: Arm D: Tiragolumab + Rituximab R/R NHLExperimental Treatment2 Interventions
Participants with R/R NHL will receive 600 mg tiragolumab Q3W + rituximab by IV infusion and SC injection (optional).
Group III: Arm C: Tiragolumab + Daratumumab R/R MMExperimental Treatment2 Interventions
Participants with R/R MM will receive 600 mg tiragolumab Q3W + daratumumab by subcutaneous (SC) injection.
Group IV: Arm B: Tiragolumab R/R NHLExperimental Treatment1 Intervention
Participants with relapsed or refractory (R/R) non-Hodgkin Lymphoma (NHL) will receive a single dose of 600 mg tiragolumab by IV infusion Q3W.
Group V: Arm A: Tiragolumab R/R MMExperimental Treatment1 Intervention
Participants with relapsed or refractory (R/R) Multiple Myeloma (MM) will receive a single dose of 600 mg tiragolumab by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tiragolumab
2020
Completed Phase 2
~460
Rituximab
1999
Completed Phase 4
~1880
Atezolizumab
2017
Completed Phase 3
~5860

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,541 Previous Clinical Trials
567,990 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,202 Previous Clinical Trials
889,995 Total Patients Enrolled
~7 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top